SecBot SecBot
144 ·Filed Apr 15, 2026

RVMDW

Revolution Medicines, Inc.
BEARISH
Impact 6/10
Horizondays Processed7mo ago SEC0001950047-26-003525
Form 144, notice of proposed sale of securities
Actionable Insight ▼ Bearish

Traders should monitor for actual execution of this sale, as large insider selling by a director and officer may signal lack of confidence, especially amid a pattern of sustained divestment. Consider hedging or reducing exposure ahead of potential downward price pressure.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.88
T+0 close · Apr 15, 2026 · via day close
Latest settled
+376.60%
T+60 · $8.96
Vs SPY
+369.55%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 16 $1.88entry
  2. T+1 · 7mo ago 0.00%α −1.21% · $1.88
  3. T+5 · 7mo ago 0.00%α −0.98% · $1.88
  4. T+20 · 6mo ago 0.00%α −5.82% · $1.88
  5. T+60 · 4mo ago +376.60%α +369.55% · $8.96
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mark A. Goldsmith, a director and officer of Revolution Medicines, intends to sell up to 120,000 shares of common stock, valued at approximately $17.6 million, under a 10b5-1 plan. The sale is scheduled for April 15, 2026, and follows prior 10b5-1 sales by Goldsmith and affiliated trusts totaling over $4.6 million in March 2026.

Key Facts

  • Mark A. Goldsmith is a director and officer of Revolution Medicines (RVMDW).
  • He filed a Form 144 to sell up to 120,000 shares of common stock, valued at $17,641,200.
  • The sale is scheduled for April 15, 2026, under a 10b5-1 plan.
  • Goldsmith and affiliated trusts executed over $4.6 million in 10b5-1 sales in early March 2026.
  • Total proposed and recent sales by Goldsmith exceed $22 million in the past month.

Financial Impact

$17.6 million in planned insider selling, part of a broader $22+ million divestment trend by the insider and related parties

insider ownershipmarket sentimentpotential dilution perception

Risk Factors

  • Perceived lack of confidence from insider selling could negatively impact investor sentiment.
  • Execution of the sale could increase market supply and contribute to downward price pressure.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-003525
Document: 0001950047-26-003525-index.html0001950047-26-003525
Document: 0001950047-26-003525.txt0001950047-26-003525

Track record

8 reports on RVMDW

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Apr 17, 202630w ago 8-K Bearish 8/10 Entry $1.88 to $9.07 ▼ −382.45% −375.67% vs SPY
  2. Apr 16, 202630w ago 8-K Neutral 6/10 Entry $1.88 to $8.98 ▲ +377.66% +371.52% vs SPY
  3. Apr 15, 202630w ago 424B5 Neutral 6/10 Entry $1.88 to $8.96 ▲ +376.60% +369.55% vs SPY
  4. Apr 15, 202630w ago 424B5 Bearish 7/10 Entry $1.88 to $8.96 ▼ −376.60% −369.55% vs SPY
  5. Apr 15, 202630w ago 144 Bearish 6/10 Viewing Entry $1.88 to $8.96 ▼ −376.60% −369.55% vs SPY
  6. Apr 13, 202631w ago 424B5 Bearish 7/10 Entry $1.88 No price data
  7. Apr 13, 202631w ago 424B5 Bearish 7/10 Entry $1.88 No price data
  8. Apr 13, 202631w ago 8-K Bullish 8/10 Entry $1.88 No price data
Showing 8 of 8

US Market Status

Market Closed · Opens in 8h 24m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 15, 2026